653 related articles for article (PubMed ID: 17367311)
21. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T; Pohl M; Misselwitz J; John U
Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
[TBL] [Abstract][Full Text] [Related]
23. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
Wade VL; Gleason BL
Ann Pharmacother; 2004; 38(7-8):1278-82. PubMed ID: 15187210
[TBL] [Abstract][Full Text] [Related]
24. Determinants and patterns of renin-angiotensin system inhibitors' prescription in the first year following kidney transplantation.
Thilly N; Bayat S; Alla F; Kessler M; Briançon S; Frimat L
Clin Transplant; 2008; 22(4):439-46. PubMed ID: 18318741
[TBL] [Abstract][Full Text] [Related]
25. Usual ACE inhibitor therapy in CKD patients is associated with lower plasma aldosterone levels than usual angiotensin receptor blocker therapy.
Haddad N; Rajan J; Nagaraja HN; Agarwal AK; Hebert LA
Kidney Blood Press Res; 2007; 30(5):299-305. PubMed ID: 17641546
[TBL] [Abstract][Full Text] [Related]
26. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?
Ryan MJ; Tuttle KR
Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):443-9. PubMed ID: 18695383
[TBL] [Abstract][Full Text] [Related]
27. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
29. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
30. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
Kuriyama S; Tomonari H; Ohtsuka Y; Ohkido I; Hosoya T
Nihon Jinzo Gakkai Shi; 2003; 45(4):367-71. PubMed ID: 12806973
[TBL] [Abstract][Full Text] [Related]
31. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
Hillebrand U; Suwelack BM; Loley K; Lang D; Reuter S; Amler S; Pavenstädt H; Hausberg M; Büssemaker E
Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
[TBL] [Abstract][Full Text] [Related]
32. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
33. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
34. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2010 Apr; 55(4):671-81. PubMed ID: 20097461
[TBL] [Abstract][Full Text] [Related]
35. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
36. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP
Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535
[TBL] [Abstract][Full Text] [Related]
37. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.
Spinar J; Vítovec J; Soucek M; Dusek L; Pavlík T;
Vnitr Lek; 2009 May; 55(5):481-8. PubMed ID: 19514614
[TBL] [Abstract][Full Text] [Related]
38. Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution.
Onuigbo MA
Nephron Clin Pract; 2009; 113(2):c63-9, discussion c70. PubMed ID: 19602900
[TBL] [Abstract][Full Text] [Related]
39. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
Saklayen MG; Gyebi LK; Tasosa J; Yap J
J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
[TBL] [Abstract][Full Text] [Related]
40. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
Cotter J; Oliveira P; Cunha P; Polónia J
Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
